However, due to the low proportion of unresectable HCC patients treated with Lenvatinib and PD-1 Inhibitors as a conversion therapy and successfully undergo conversion surgery (63–65), few patients could be included in our study. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.